Based on the synergistic effects of ACTL6A knockdown and IACS-010759 treatment in vitro, we investigated the effect of this combined treatment on tumor growth in vivo. We performed a heterotopic tumor model using control (shNTC) or ACTL6A-depleted (shACTL6A) MOC2 cells subcutaneously injected into B6J.Rag2 Il2rg double KO mice, which allowed us to study drug effects in isolation without tumor-immune responses. The gene discussed is RAG2; the disease is neoplasm.